These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 34677236)
1. Clinical Outcomes from Dose-Reduced Radiotherapy to the Prostate in Elderly Patients with Localized Prostate Cancer. Samson N; Khanolkar RA; Quirk S; Quon H; Roumeliotis M; Balogh A; Sia M; Thind K; Husain S; Martell K Curr Oncol; 2021 Sep; 28(5):3729-3737. PubMed ID: 34677236 [TBL] [Abstract][Full Text] [Related]
2. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation. Baumann BC; Baumann JC; Christodouleas JP; Soffen E Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422 [TBL] [Abstract][Full Text] [Related]
3. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database. Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208 [TBL] [Abstract][Full Text] [Related]
4. Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial. Sargos P; Mottet N; Bellera C; Richaud P BJU Int; 2020 Jun; 125(6):810-816. PubMed ID: 30946523 [TBL] [Abstract][Full Text] [Related]
5. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes. Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201 [TBL] [Abstract][Full Text] [Related]
6. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium. Ishiyama H; Kamitani N; Kawamura H; Kato S; Aoki M; Kariya S; Matsumura T; Kaidu M; Yoshida K; Hashimoto Y; Noda Y; Lim KHC; Kawase T; Takahashi T; Inaba K; Kumano M; Yoshikawa N; Yoshioka Y; Nakamura K; Hiratsuka J; Itami J; Hayakawa K Brachytherapy; 2017; 16(3):503-510. PubMed ID: 28222973 [TBL] [Abstract][Full Text] [Related]
7. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy. Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132 [TBL] [Abstract][Full Text] [Related]
8. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer. Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658 [TBL] [Abstract][Full Text] [Related]
9. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer. Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671 [TBL] [Abstract][Full Text] [Related]
10. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan. Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471 [TBL] [Abstract][Full Text] [Related]
11. Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR). Kim YJ; Ahn H; Kim CS; Kim YS Radiat Oncol; 2020 Oct; 15(1):234. PubMed ID: 33032643 [TBL] [Abstract][Full Text] [Related]
12. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125 [TBL] [Abstract][Full Text] [Related]
13. Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series. Wilcox SW; Aherne NJ; McLachlan CS; McKay MJ; Last AJ; Shakespeare TP J Med Imaging Radiat Oncol; 2015 Feb; 59(1):125-33. PubMed ID: 25588566 [TBL] [Abstract][Full Text] [Related]
17. Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Tward JD; O'Neil B; Boucher K; Kokeny K; Lowrance WT; Lloyd S; Cannon D; Stephenson RA; Agarwal N; Farr T; Petragallo R; Sherar NZ; Kunz I; Hofer A; Courdy S; Shrieve DC; Dechet C Clin Genitourin Cancer; 2020 Aug; 18(4):274-283.e5. PubMed ID: 32335059 [TBL] [Abstract][Full Text] [Related]
18. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon ion radiotherapy for prostate cancer. Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Nakano T; Tsujii H Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):78-84. PubMed ID: 18456419 [TBL] [Abstract][Full Text] [Related]
19. Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer. Ghadjar P; Oesch SL; Rentsch CA; Isaak B; Cihoric N; Manser P; Thalmann GN; Aebersold DM Radiat Oncol; 2014 May; 9():122. PubMed ID: 24885327 [TBL] [Abstract][Full Text] [Related]
20. Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation. Hou WH; Huang CY; Wang CC; Lan KH; Chen CH; Yu HJ; Liu SP; Lai MK; Pu YS; Cheng JC Asian J Androl; 2017; 19(5):596-601. PubMed ID: 27506334 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]